Glaukos’ Net Sales Increase 37 Percent in Q3-2017

November 10, 2017: By Jon Swedien

GlaukosGlaukos’ net sales in Q3-2017 totaled $40.4 million, an increase of 37 percent compared with Q3-2016, the San Clemente, California, company announced Nov. 7.

Glaukos reaffirmed its 2017 net sales guidance of $155 million to $160 million. The range was lowered Sept. 14 from earlier guidance of $162 million to $167 million.

Operating expenses for Q3-2017 rose 38 percent to $33.9 million, compared with $24.7 million for Q3-2016. Income from operations was 700 thousand for Q3-2017, compared with $1 million for Q3-2016. Net income for Q3-2017 was $1.3 million, or $0.04 per diluted share, compared with $1.2 million, or $0.03 per diluted share, for Q3-2016, Glaukos said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Boy, 13, is First Patient Treated Commercially with Luxturna

Wet AMD Patients Regain Vision with Patch of Stem Cell-Derived RPE Cells, Moorfields Reports

ASCRS Meeting Returns to April Date in 2018, Avoiding Scheduling Conflicts

US FDA Approves Lucentis Prefilled Syringe for Diabetic Retinopathy, Diabetic Macular Edema

FDA Accepts pSivida’s Filing for Durasert as Treatment for Posterior Segment Uveitis

Eylea Meets Primary Endpoint in Phase III Trial for Nonproliferative Diabetic Retinopathy

Bascom Palmer Receives $12 Million Gift to Establish Research Center

SemaThera Announces $2 Million Financing, Licensing Deal for DME Candidate in China, Japan

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023